EGRX Eagle Pharmaceuticals, Inc.

69.31
+0  (0%)
Previous Close 69.31
Open 65.93
Price To book 10.14
Market Cap 1.07B
Shares 15,435,000
Volume 823,842
Short Ratio 12.13
Av. Daily Volume 383,200

SEC filingsSee all SEC filings

  1. 8-K - Current report 17521929
  2. 8-K - Current report 17521036
  3. 8-K - Current report 17514674
  4. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 17514670
  5. CT ORDER - Confidential treatment order 162070100

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA submission announced January 3, 2017.
Ready-to-dilute (RTD) Pemetrexed Injection
Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma
Rolling NDA filing initiated November 11, 2016.
Ryanodex
Exertional heat stroke (EHS)
Tentative approval July 2 2014. Teva has also received orphan drug and related pediatric exclusivity expiring in September 2015 and May 2016 for the CLL and NHL indications, respectively.
EP-3101 (bendamustine RTD)
Chronic lymphocytic leukemia; Indolent non-Hodgkin’s lymphoma - cancer
CRL March 18 2016. FDA requested further characterization of bivalirudin-related substances in the drug product
KANGIO (bivalirudin injection)
Percutaneous Coronary Intervention (PCI) and Percutaneous Transluminal Coronary Angioplasty (PTCA)
Approved December 24 2015
Docetaxel Injection
Breast, non-small cell lung, prostate gastric adenocarcinoma, and head and neck cancer
Approved July 22, 2014 under priority review
Ryanodex
Malignant hyperthermia - cancer

Latest News

  1. New Strong Sell Stocks for January 16th
  2. EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  3. EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  4. Eagle Pharmaceuticals, Inc. – Value Analysis (NASDAQ:EGRX) : January 10, 2017
  5. Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : January 9, 2017
  6. Eagle Pharma downgraded by Mizuho
  7. EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  8. Eagle Pharmaceuticals to Present at J.P. Morgan 35th Annual Healthcare Conference
  9. Eagle Pharmaceuticals’ Pemetrexed NDA Submitted for Review
  10. Eagle Pharmaceuticals’ Pemetrexed NDA Submitted for Review
  11. Myriad Genetics' Unit Releases Favorable Data on Vectra DA
  12. EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure,
  13. Eagle Pharmaceuticals Announces David Pernock as President and Chief Commercial Officer
  14. Eagle Pharmaceuticals Announces David Pernock as President and Chief Commercial Officer
  15. EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  16. Eagle Pharmaceuticals Reports Positive Results from Pivotal Animal Study Supporting the Efficacy of RYANODEX for Exertional Heat Stroke
  17. Why Eagle Pharmaceuticals (EGRX) Could Shock the Market Soon
  18. Hedge Funds Aren’t Crazy About Photronics, Inc. (PLAB) Anymore
  19. Increased Earnings Estimates Seen for Eagle Pharmaceuticals (EGRX): Can It Move Higher?
  20. The Zacks Analyst Blog Highlights: Best Buy, Edgewell Personal Care and Eagle Pharma

SEC Filings

  1. 8-K - Current report 17521929
  2. 8-K - Current report 17521036
  3. 8-K - Current report 17514674
  4. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 17514670
  5. CT ORDER - Confidential treatment order 162070100
  6. 8-K - Current report 162059529
  7. 8-K - Current report 162050160
  8. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 162045441
  9. CT ORDER - Confidential treatment order 162036798
  10. 10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405] 162025570